Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

Figure 2

Maximal percent change in plasma protein concentration from C1D1 to C2D28 by patient. (A) sKIT. (B) VEGF-A. (C) sVEGFR-2. (D) sVEGFR-3. Light gray bars denote patients with triple-negative disease. Broken horizontal lines denote median values for each protein. C, cycle; D, day; sKIT, soluble KIT; sVEGFR, soluble vascular endothelial growth factor receptor; VEGF, vascular endothelial growth factor.

Back to article page